You are here

Article info

Article menu

Download PDFPDF

Inflammatory arthritis
Viewpoint
Costs of drugs for treatment of rheumatic diseases

Authors

  • Rene Westhovens Department of Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Rheumatology University Hospital Leuven, Leuven, Belgium PubMed articlesGoogle scholar articles
  • Lieven Annemans Department of Public Health, I-CHER Interuniversity Centre for Health Economics Research, Ghent University, Ghent, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Rene Westhovens; rene.westhovens{at}uzleuven.be
View Full Text

Citation

Westhovens R, Annemans L
Costs of drugs for treatment of rheumatic diseases
RMD Open 2016;2:e000259. doi: 10.1136/rmdopen-2016-000259

Publication history

  • Received May 11, 2016
  • Revision received July 19, 2016
  • Accepted July 21, 2016
  • First published September 12, 2016.
Online issue publication 
July 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/